Noninvasive characterization of tumor angiogenesis and oxygenation in bevacizumab-treated recurrent glioblastoma by using dynamic susceptibility MRI: secondary analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. by Kickingereder, Philipp et al.








Noninvasive characterization of tumor angiogenesis and oxygenation in
bevacizumab-treated recurrent glioblastoma by using dynamic susceptibility
MRI: secondary analysis of the European Organization for Research and
Treatment of Cancer 26101 Trial.
Kickingereder, Philipp ; Brugnara, Gianluca ; Hansen, Mikkel Bo ; Nowosielski, Martha ; Pflüger, Irada
; Schell, Marianne ; Isensee, Fabian ; Foltyn, Martha ; Neuberger, Ulf ; Kessler, Tobias ; Sahm, Felix ;
Wick, Antje ; Heiland, Sabine ; Weller, Michael ; Platten, Michael ; von Deimling, Andreas ;
Maier-Hein, Klaus H ; Østergaard, Leif ; van den Bent, Martin J ; Gorlia, Thierry ; Wick, Wolfgang ;
Bendszus, Martin
Abstract: Background Relevance of antiangiogenic treatment with bevacizumab in patients with glioblas-
toma is controversial because progression-free survival benefit did not translate into an overall survival
(OS) benefit in randomized phase III trials. Purpose To perform longitudinal characterization of intratu-
moral angiogenesis and oxygenation by using dynamic susceptibility contrast agent-enhanced (DSC) MRI
and evaluate its potential for predicting outcome from administration of bevacizumab. Materials and
Methods In this secondary analysis of the prospective randomized phase II/III European Organization
for Research and Treatment of Cancer 26101 trial conducted between October 2011 and December 2015
in 596 patients with first recurrence of glioblastoma, the subset of patients with availability of anatomic
MRI and DSC MRI at baseline and first follow-up was analyzed. Patients were allocated into those
administered bevacizumab (hereafter, the BEV group; either bevacizumab monotherapy or bevacizumab
with lomustine) and those not administered bevacizumab (hereafter, the non-BEV group with lomustine
monotherapy). Contrast-enhanced tumor volume, noncontrast-enhanced T2 fluid-attenuated inversion
recovery (FLAIR) signal abnormality volume, Gaussian-normalized relative cerebral blood volume (nr-
CBV), Gaussian-normalized relative blood flow (nrCBF), and tumor metabolic rate of oxygen (nTMRO2)
was quantified. The predictive ability of these imaging parameters was assessed with multivariable Cox
regression and formal interaction testing. Results A total of 254 of 596 patients were evaluated (mean
age, 57 years ± 11; 155 men; 161 in the BEV group and 93 in non-BEV group). Progression-free survival
was longer in the BEV group (3.7 months; 95% confidence interval [CI]: 3.0, 4.2) compared with the
non-BEV group (2.5 months; 95% CI: 1.5, 2.9; P = .01), whereas OS was not different (P = .15). The
nrCBV decreased for the BEV group (-16.3%; interquartile range [IQR], -39.5% to 12.0%; P = .01), but
not for the non-BEV group (1.2%; IQR, -17.9% to 23.3%; P = .19) between baseline and first follow-up.
An identical pattern was observed for both nrCBF and nTMRO2 values. Contrast-enhanced tumor and
noncontrast-enhanced T2 FLAIR signal abnormality volumes decreased for the BEV group (-66% [IQR,
-83% to -35%] and -33% [IQR, -71% to -5%], respectively; P < .001 for both), whereas they increased for
the non-BEV group (30% [IQR, -17% to 98%], P = .001; and 10% [IQR, -13% to 82%], P = .02, respec-
tively) between baseline and first follow-up. None of the assessed MRI parameters were predictive for
OS in the BEV group. Conclusion Bevacizumab treatment decreased tumor volumes, angiogenesis, and
oxygenation, thereby reflecting its effectiveness for extending progression-free survival; however, these
parameters were not predictive of overall survival (OS), which highlighted the challenges of identifying
patients that derive an OS benefit from bevacizumab. © RSNA, 2020 Online supplemental material is
available for this article. See also the editorial by Dillon in this issue.
DOI: https://doi.org/10.1148/radiol.2020200978
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Background: Relevance of antiangiogenic treatment with bevacizumab in patients with glioblastoma is controversial because progres-
sion-free survival benefit did not translate into an overall survival (OS) benefit in randomized phase III trials.
Purpose: To perform longitudinal characterization of intratumoral angiogenesis and oxygenation by using dynamic susceptibility 
contrast agent–enhanced (DSC) MRI and evaluate its potential for predicting outcome from administration of bevacizumab.
Materials and Methods: In this secondary analysis of the prospective randomized phase II/III European Organization for Research and 
Treatment of Cancer 26101 trial conducted between October 2011 and December 2015 in 596 patients with first recurrence of 
glioblastoma, the subset of patients with availability of anatomic MRI and DSC MRI at baseline and first follow-up was analyzed. 
Patients were allocated into those administered bevacizumab (hereafter, the BEV group; either bevacizumab monotherapy or beva-
cizumab with lomustine) and those not administered bevacizumab (hereafter, the non-BEV group with lomustine monotherapy). 
Contrast-enhanced tumor volume, noncontrast-enhanced T2 fluid-attenuated inversion recovery (FLAIR) signal abnormality vol-
ume, Gaussian-normalized relative cerebral blood volume (nrCBV), Gaussian-normalized relative blood flow (nrCBF), and tumor 
metabolic rate of oxygen (nTMRO
2
) was quantified. The predictive ability of these imaging parameters was assessed with multivari-
able Cox regression and formal interaction testing.
Results: A total of 254 of 596 patients were evaluated (mean age, 57 years 6 11; 155 men; 161 in the BEV group and 93 in non-
BEV group). Progression-free survival was longer in the BEV group (3.7 months; 95% confidence interval [CI]: 3.0, 4.2) compared 
with the non-BEV group (2.5 months; 95% CI: 1.5, 2.9; P = .01), whereas OS was not different (P = .15). The nrCBV decreased 
for the BEV group (216.3%; interquartile range [IQR], 239.5% to 12.0%; P = .01), but not for the non-BEV group (1.2%; IQR, 
217.9% to 23.3%; P = .19) between baseline and first follow-up. An identical pattern was observed for both nrCBF and nTMRO
2
 
values. Contrast-enhanced tumor and noncontrast-enhanced T2 FLAIR signal abnormality volumes decreased for the BEV group 
(266% [IQR, 283% to 235%] and 233% [IQR, 271% to 25%], respectively; P , .001 for both), whereas they increased for 
the non-BEV group (30% [IQR, 217% to 98%], P = .001; and 10% [IQR, 213% to 82%], P = .02, respectively) between base-
line and first follow-up. None of the assessed MRI parameters were predictive for OS in the BEV group.
Conclusion: Bevacizumab treatment decreased tumor volumes, angiogenesis, and oxygenation, thereby reflecting its effectiveness for 
extending progression-free survival; however, these parameters were not predictive of overall survival (OS), which highlighted the 
challenges of identifying patients that derive an OS benefit from bevacizumab.
© RSNA, 2020
Online supplemental material is available for this article.
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investigated the utility of these angiogenesis-related parameters 
from DSC MRI alongside standard imaging parameters, such 
as tumor volumes, from anatomic MRI for identifying subsets 
of patients who are most likely to benefit from bevacizumab by 
means of OS.
Materials and Methods
Study Design and Participants
In this secondary analysis, we analyzed MRI data from patients 
with brain tumors that were acquired as part of the prospective 
EORTC 26101 trial (NCT01290939), which was conducted 
between October 2011 and December 2015. Our study was 
performed in accordance with the Declaration of Helsinki, 
and the protocol was approved by local ethics committees and 
patients provided written informed consent (EudraCT 2010–
023218–30). The full study design and outcomes (progression-
free survival and OS) were published previously (12,13).
As described previously (14), EORTC 26101 was a pro-
spective randomized phase II and III trial in patients with first 
progression of glioblastoma after standard chemotherapy and 
radiation therapy. In brief, the phase II trial evaluated the op-
timal treatment sequence of bevacizumab and lomustine (four 
treatment arms with single agent vs sequential vs combina-
tion), whereas the subsequent phase III trial (two treatment 
arms) compared patients treated with lomustine alone with pa-
tients who were administered a combination of lomustine and 
bevacizumab (randomized at a 1:2 ratio). Overall, EORTC 
26101 included 596 patients (159 patients from phase II and 
437 patients from phase III) from 37 institutions within Eu-
rope. On the basis of the four treatment arms of the phase 
II trial (12) and the two treatment arms in the phase III trial 
(13), patients were allocated to this secondary analysis into two 
groups: (a) those administered bevacizumab (hereafter, referred 
to as the BEV group) and (b) those not administered bevaci-
zumab (hereafter, referred to as the non-BEV group) for the 
treatment at first recurrence of glioblastoma.
For our analysis, patients with availability of MRI that in-
cluded anatomic sequences (pre- and postcontrast T1-weighted, 
T2-weighted, and fluid-attenuated inversion recovery [FLAIR] 
images) and DSC MRI sequences at baseline before treatment 
and at first follow-up were selected. We excluded those patients 
with incomplete availability of precontrast T1-weighted, post-
contrast T1-weighted, FLAIR, T2-weighted, and DSC MRI 
sequences (requiring either three-dimensional acquisitions or 
two-dimensional with axial orientation; n = 287); heavy motion 
artifacts (n = 14); insufficient contrast agent administration at 
DSC MRI or at postcontrast T1-weighted imaging (n = 31); or 
because of corrupt data after Digital Imaging and Communica-
tions in Medicine data format to the Neuroimaging Informatics 
Technology Initiative data format (n = 10) (Fig 1).
MRI Examinations
MRI examinations were performed at baseline and every 6 
weeks until week 24, afterward every 3 months (13). Specifi-
cally, imaging with standardized imaging protocol was aligned 
with the consensus recommendations for a standardized brain 
Abbreviations
CI = confidence interval, DSC = dynamic susceptibility contrast en-
hanced, EORTC = European Organization for Research and Treatment 
of Cancer, FLAIR = fluid-attenuated inversion recovery, IQR = inter-
quartile range, nrCBF = Gaussian-normalized relative cerebral blood 
flow, nrCBV = Gaussian-normalized relative cerebral blood volume, 
nTMRO
2
 = Gaussian-normalized tumor metabolic rate of oxygen, 
OS = overall survival
Summary
This secondary analysis of European Organization for Research and 
Treatment of Cancer 26101 highlights the biological activity and ef-
fectiveness of bevacizumab for extending progression-free survival for 
patients with glioblastoma; however, identifying patients with overall 
survival benefit remains challenging.
Key Results
 n Compared with lomustine monotherapy, antiangiogenic treatment 
for glioblastoma with bevacizumab led to a reduction in tumor 
volumes, angiogenesis, and oxygenation (P , .001 for each).
 n Baseline or change in tumor angiogenesis and oxygenation were 
not associated with overall patient survival after bevacizumab 
treatment (P = .59–.95).
G
lioblastoma is the most common malignant primary brain 
tumor and, despite decades of research, remains among the 
most lethal of all forms of cancer. These tumors are highly angio-
genic and characterized by vascular proliferations that are sub-
stantially fueled by vascular endothelial growth factor signaling. 
The U.S. Food and Drug Administration approved the use of 
bevacizumab, a recombinant humanized monoclonal antibody 
that binds to vascular endothelial growth factor, in patients with 
recurrent glioblastoma after a number of encouraging (but un-
controlled) phase II trials with promising response rates on MRI 
scans and delayed tumor progression (1,2). Subsequent random-
ized phase III trials (Avastin in Glioblastoma, or AVAglio; Radia-
tion Therapy Oncology Group, or RTOG, 0825; and European 
Organization for Research and Treatment of Cancer [EORTC] 
26101 [3–5]) confirmed the significantly longer progression-free 
survival with the use of bevacizumab; however, this did not trans-
late into an overall survival (OS) benefit, neither in the setting of 
newly diagnosed tumors when adding bevacizumab to standard 
treatment nor at first recurrence when comparing bevacizumab 
with lomustine chemotherapy. Despite the strong biologic ratio-
nale for the use of antiangiogenic agents in glioblastoma, the re-
sults from the available randomized phase III trials indicate that 
bevacizumab may not be beneficial in unselected populations of 
patients with glioblastoma (6). Consequently, there has been a 
strong interest in identifying predictive biomarkers for selecting 
patient subsets that are most likely to benefit from bevacizumab 
(7,8). Specifically, assessment of the tumor vasculature through 
dynamic susceptibility-weighted contrast agent–enhanced (DSC) 
MRI may offer a biologically meaningful surrogate for predict-
ing treatment response to antiangiogenic agents (9–11).
We conducted an exploratory secondary analysis of the ran-
domized controlled multicenter phase II and III EORTC 26101 
trial with in-depth longitudinal characterization of intratumoral 
angiogenesis at DSC MRI including quantification of blood vol-
ume, blood flow, and metabolic rate of oxygen. Moreover, we 
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discretion of the individual institution (sequence 
parameters listed in Appendix E1 [online]).
MRI Postprocessing
A flowchart depicting the analysis workflow is 
shown in Figure 1 with detailed description in Ap-
pendix E2 (online). MRI postprocessing was per-
formed by G.B., a radiology resident with 5 years of 
experience in image processing, and subsequently 
checked by P.K., a board-certified radiologist with 
7 years of experience. Specifically, processing of 
the anatomic sequences included automated deep 
learning–based brain extraction (16) followed by 
image registration and automated deep learning–
based voxel-wise segmentation with volumetric 
quantification of the contrast-enhanced tumor 
volume and the noncontrast-enhanced T2 FLAIR 
signal abnormality volume as described previously 
(14,16). All patients reported in our study were 
also included in previous works. However, there is 
no relevant overlap with our study, which analyzes 
the DSC MRI data and aims to identify prognos-
tic and/or prospective imaging biomarkers.
Processing of DSC MRI sequences for calcu-
lating cerebral blood flow and cerebral blood vol-
ume maps was performed with dedicated software 
(Olea Sphere version 2.3, Olea Medical, La Ciotat, 
France). Specifically, whole-brain relative cerebral 
blood volume and relative cerebral blood flow maps 
were generated as previously described (17). Post-
processing of DSC MRI data for calculating tumor 
metabolic rate of oxygen maps was performed with 
Cercare Medical Neurosuite (Cercare Medical, Aar-
hus, Denmark), as previously described (18). Image 
intensity correction of the relative cerebral blood 
volume, relative cerebral blood flow, and tumor 
metabolic rate of oxygen maps was performed by 
calculating Gaussian-normalized relative cerebral 
blood volume (nrCBV), Gaussian-normalized rela-
tive cerebral blood flow (nrCBF), and Gaussian-
normalized tumor metabolic rate of oxygen (nT-
MRO
2
) maps, as suggested by Ellingson et al (19). 
The median nrCBV, nrCBF, and nTMRO
2
 values 
at baseline MRI and the dynamics in the nrCBV, 
nrCBF, and nTMRO
2
 values between baseline and 
first follow-up MRI was calculated from the con-
trast-enhanced tumor volume.
Outcomes
The objective of our study was to identify pre-
dictive imaging biomarkers for stratifying treat-
ment outcome (by means of OS) to bevacizumab 
therapy in patients with recurrent glioblastoma. 
OS was calculated from the date of randomiza-
tion until death or last follow-up. Progression-free survival was 
calculated from the date of randomization until the date of 
tumor progression (as assessed by local Response Assessment 
tumor imaging protocol in clinical trials (15) and included 
pre- and postcontrast T1-weighted, T2-weighted, and FLAIR 
images. In addition, optional DSC MRI was performed at the 
Figure 1: Flowchart of the procedures and analysis performed within the study. BEV = beva-
cizumab, cT1-w = postcontrast T1-weighted, DSC = dynamic susceptibility contrast-enhanced 
imaging, DICOM = Digital Imaging and Communications in Medicine, EORTC = European 
Organization for Research and Treatment of Cancer, FLAIR = fluid-attenuated inversion recovery, 
nrCBF = Gaussian-normalized relative cerebral blood flow, nrCBV = Gaussian-normalized relative 
cerebral blood volume, nrTMRO2 = Gaussian-normalized tumor metabolic rate of oxygen,T1-w = 
precontrast T1 weighted, T2-w = T2 weighted.
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volumes; and median nrCBV, nrCBF, and nTMRO
2
 values at 
baseline and the dynamics in all of these parameters between 
baseline and first follow-up MRI) and the effect of bevacizumab 
treatment was evaluated by constructing Cox proportional haz-
ards regression models for each imaging parameter. Specifically, 
each model contained one imaging parameter, or continuous 
scale, as the putative biomarker; the treatment group (ie, BEV 
vs non-BEV); the treatment-by-biomarker interaction term to 
differentiate whether the putative biomarker is prognostic or 
predictive (20); and the sequence of treatment to rule out a con-
founding effect of different treatment regimens (ie, bevacizumab 
with lomustine at progression salvage treatment at the investiga-
tor’s best choice vs bevacizumab alone at progression switch to 
bevacizumab with lomustine vs lomustine alone at progression 
in Neuro-oncology reading as part of the initial analysis of the 
EORTC 26101 trial [13]) or death, whichever occurred first.
Statistical Analysis
Statistical analysis was performed by using software (R ver-
sion 3.6.2; R Foundation for Statistical Computing, Vienna, 
Austria) by P.K. and T.G., a biostatistician with 21 years of 
experience. The differences in clinical, molecular, and extracted 
quantitative imaging parameters between the BEV and non-
BEV groups and between baseline and first follow-up MRI was 
assessed (Appendix E3 [online]).
The potential predictive association in terms of OS between 
the extracted imaging parameters (ie, contrast-enhanced tumor 
volumes; noncontrast-enhanced T2 FLAIR signal abnormality 
Table 1: Baseline Patient Characteristics
Parameter BEV Group (n = 161) Non-BEV Group (n = 93) P Value
Clinical characteristics
 Sex
  No. of women 64 (40) 35 (38) .84
  No. of men 97 (60) 58 (62)
 Median age (y)* 58 (51–64) 60 (51–64) .73
 WHO performance status
  0 54 (34) 33 (35) .86
  1 107 (66) 60 (65)
 Use of glucocorticoids
  No 77 (48) 57 (61) .05
  Yes 84 (52) 36 (39)
 Sequence of treatment
  BEV (at PD combination treatment with BEV and LOM) 40 (25) … NA
  Combination BEV and LOM (at PD investigator’s choice) 121 (75) …
  LOM (at PD treatment with BEV) … 61 (66)
  LOM (at PD investigator’s choice) … 32 (33)
Molecular characteristics
 MGMT promoter methylation status
  Methylated 52 (32) 33 (35) .75
  Unmethylated 63 (39) 32 (34)
  Undetermined or missing data 46 (29) 28 (30)
 GCIMP status
  Positive 3 (1) 2 (2) .99
  Negative 158 (99) 91 (98)
Image acquisition characteristics
 Median interval baseline MRI to randomization (d)* 2 (125) 2 (125) .93
 Median interval baseline MRI to first follow-up MRI (d)* 46 (42250) 45 (42249) .16
Quantitative MRI parameters at baseline MRI
 Median contrast-enhanced tumor volume (cm3)* 13.77 (6.09230.28) 15.04 (7.36230.46) .69
 Median noncontrast-enhanced T2-FLAIR signal abnormality volume (cm3)* 63.63 (35.082106.09) 62.38 (30.09298.55) .94
 Median nrCBV* 1.00 (0.6821.37) 0.99 (0.6821.42) .78
 Median nrCBF* 1.03 (0.7421.40) 1.04 (0.6921.46) .71
 Median nTMRO
2
* 0.98 (0.6121.34) 0.96 (0.7021.39) .65
Note.—Unless otherwise specified, data are number of patients and data in parentheses are percentages. BEV = bevacizumab, FLAIR = flu-
id-attenuated inversion recovery, GCIMP = glioma-CpG island methylator phenotype, LOM = lomustine, MGMT = O6-methylguanine-
DNA methyltransferase, NA = not assessed, nrCBF = Gaussian-normalized relative cerebral blood flow, nrCBV = Gaussian-normalized 
relative cerebral blood volume, nTMRO
2
 = Gaussian-normalized tumor metabolic rate of oxygen, PD = progressive disease, WHO = World 
Health Organization.
* Data in parentheses are interquartile range.
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the change in the non-BEV group (P  .004, each; Table 2, 
Fig E1 [online]). Specifically, the contrast-enhanced tumor 
volumes decreased for patients in the BEV group (median 
change, 266%; interquartile range [IQR], 283% to 235%; 
P , .001), whereas they increased for patients in the non-
BEV group (median change between baseline MRI and first 
follow-up MRI, 30%; IQR, 217% to 98%; P = .001; Fig 2, 
A, Table 2). Similarly, the unenhanced T2 and FLAIR signal 
abnormality volumes decreased for patients in the BEV group 
(median change between baseline MRI and first follow-up 
MRI, 233%; IQR, 271% to 25%; P , .001), whereas they 
increased for patients in the non-BEV group (median change, 
10%; IQR, 213% to 82%; P = .02; Fig 2, B, Table 2).
The nrCBV, which reflects tumor angiogenesis, decreased 
in the BEV group (median change between baseline MRI and 
first follow-up MRI, 216%; IQR, 241% to 13%; P , .001) 
but not for the non-BEV group (median change between base-
line MRI and first follow-up MRI, 1%; IQR, 212% to 22%; 
P = .79) (Fig 3, A, Table 2). There was a close positive correla-
tion between nrCBV and nrCBF values (which reflects intra-
tumoral blood flow) as well as nTMRO
2
 values (which reflects 
intratumoral oxygenation) both at baseline (nrCBF and nT-
MRO
2
 Pearson correlation coefficients, 0.99 [95% confidence 
interval {CI}: 0.98, 0.99; P , .001] and 0.97 [95% CI: 0.96, 
0.97; P , .001], respectively) and in response to treatment 
(nrCBF and nTMRO
2
 Pearson correlation coefficients, 0.97 
[95% CI: 0.96, 0.98; P , .001] and 0.92 [95% CI: 0.90, 0.94; 
P , .001], respectively; Figs E2, E3 [online]). Both nrCBF 
and nTMRO
2
 decreased for the BEV group (nrCBF vs nT-
MRO
2
 median change between baseline MRI and first follow-
up MRI, 218% [IQR, 236% to 12%; P , .001] vs 218% 
[IQR, 239% to 17%; P = .001], respectively) but not for the 
non-BEV group (nrCBF vs nTMRO
2
 median change between 
baseline MRI and first follow-up MRI, 1% [IQR, 215% to 
switch to bevacizumab vs lomustine alone at progression salvage 
treatment at the investigator’s best choice). A significant treat-
ment-by-biomarker interaction term would indicate that the 
treatment effect differs by imaging parameter and thus would 
correspond to a predictive imaging biomarker (20). P values 
from individual models were adjusted for multiple comparison 
by using the false discovery rate procedure.
Multivariable Cox proportional hazards regression modeling 
for OS was separately performed for both BEV and non-BEV 
groups to assess the independent significance of imaging param-
eters. The model was adjusted for potential clinical and molecular 
confounders (age, sex, World Health Organization performance 
status, glucocorticoid administration at baseline, O6-methylgua-
nine-DNA methyltransferase promoter methylation status, and 
glioma-CpG island methylator phenotype status). P values less 
than .05 were considered to indicate statistical significance.
Results
Patient Characteristics
Among 596 patients in the EORTC 26101 phase II and III 
study, a subset of 254 patients (42.6%) met the criteria for this 
secondary analysis (Fig 1). These 254 patients included 161 
patients (63.4%) in the BEV group and 93 patients (36.6%) 
in the non-BEV group. Baseline clinical, molecular, and image 
characteristics were equally distributed between the BEV and 
non-BEV groups (Table 1).
Differences in Tumor Volumes, Angiogenesis, and 
Oxygenation Characteristics
The extracted quantitative imaging parameters showed a sig-
nificant change in response to treatment by assessing their 
dynamics between baseline MRI and first follow-up MRI, 
and the change in the BEV group differed significantly from 
Table 2: Dynamics of Quantitative Imaging Parameters in Response to Treatment
Parameter BEV Group (n = 161) Non-BEV Group (n = 93) P Value
Contrast-enhanced tumor volume
 Absolute change (cm3) 27.40 (216.64 to 22.22) 3.13 (23.19 to 13.78) ,.001
 Relative change (%) 266 (283 to 235) 30 (217 to 98) ,.001
Noncontrast-enhanced T2 FLAIR signal abnormality volume
 Absolute change (cm3) 217.31 (257.91 to 21.57) 4.76 (28.96 to 35.33) ,.001
 Relative change (%) 233 (271 to 25) 10 (213 to 82) ,.001
nrCBV
 Absolute change 20.14 (20.39 to 0.12) 0.02 (20.15 to 0.15) ,.001
 Relative change (%) 216 (241 to 13) 1 (212 to 22) ,.001
nrCBF
 Absolute change 20.15 (20.37 to 0.11) 0.01 (20.13 to 0.15) ,.001
 Relative change (%) 218 (236 to 12) 1 (215 to 19) ,.001
nTMRO
2
 Absolute change 20.14 (20.39 to 0.16) 0 (20.12 to 0.15) .004
 Relative change (%) 218 (239 to 17) 0 (212 to 18) .001
Note.—Data in parentheses are interquartile range. P values derived from a Wilcoxon rank sum test comparing the distribution of a given 
imaging parameter between the BEV and non-BEV group. BEV = bevacizumab, FLAIR = fluid-attenuated inversion recovery, nrCBF = 
Gaussian-normalized relative cerebral blood flow, nrCBV = Gaussian-normalized relative cerebral blood volume, nTMRO
2
 = Gaussian-
normalized tumor metabolic rate of oxygen.
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variable and the hazard ratio of 1.04 (95% CI: 1.01, 1.06; P 
= .001) for the imaging parameter indicated superior OS for 
those patients in the non-BEV subgroup with greater reduc-
tion in contrast-enhanced tumor volume (Fig E5 [online]). 
There was no predictive association in terms of OS between 
any of the extracted imaging parameters and the effect of 
bevacizumab treatment (false discovery rate–adjusted P . 
.05 for the interaction term in each of the remaining mod-
els; Table 3).
Multivariable Cox proportional hazards regression adjusted 
for clinical and molecular parameters demonstrated an indepen-
dent prognostic significance (in terms of OS) for the baseline 
contrast-enhanced tumor volume (BEV vs non-BEV group haz-
ard ratio, 1.02 [95% CI: 1.01, 1.04; P = .01] and 1.03 [95% 
CI: 1.01, 1.06; P = .01], respectively) (Figs 4, 5, A). Notably, 
the nrCBV dynamics between baseline and first follow-up MRI 
19%; P = .97] and 0% [IQR, 212% to 18%; P = .64], respec-
tively; Fig 3, B, C, Table 2).
Progression-Free Survival and OS
Progression-free survival was longer in the BEV group (3.7 
months; 95% CI: 3.0, 4.2) than in the non-BEV group (2.5 
months; 95% CI: 1.5, 2.9) (P = .01), whereas OS was not 
different between the BEV group (8.9 months; 95% CI: 7.7, 
10.2) and the non-BEV group (9.8 months; 95% CI: 8.6, 
12.1) (P = .15; Fig E4 [online]). A quantitative interaction 
between the extracted imaging parameters and the treatment 
variable was found for the dynamics in contrast-enhanced 
tumor volumes between baseline and first follow-up (Table 
3). Specifically, the model’s hazard ratio of 0.96 (95% CI: 
0.94, 0.98; false discovery rate–adjusted P = .011) for the 
interaction term between imaging parameter and treatment 
Figure 2: A, Contrast-enhanced tumor volumes and, B, noncontrast-enhanced T2 fluid-attenuated inversion recovery (FLAIR) signal abnormality 
volumes at baseline and first follow-up MRI and the dynamics in these volumes between the two points (increasing volume and decreasing volume). 
BEV = bevacizumab.
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Figure 3: Distribution of, A, Gaussian-normalized relative cerebral blood volume (nrCBV), B, Gaussian-normalized relative cerebral 
blood flow (nrCBF), and, C, tumor metabolic rate of oxygen (nTMRO2) values at baseline and first follow-up MRI and the dynamics be-
tween these two points (increasing nrCBV, nrCBF, or nTMRO2; or decreasing nrCBV, nrCBF or nTMRO2). BEV = bevacizumab.
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Table 3: Cox Proportional Hazards Regression Models for Assessing the Interaction Between the Extracted Imaging Parameters 
and the Effect of Bevacizumab Treatment on Overall Survival
Parameter Hazard Ratio P Value FDR-adjusted P Value
Baseline MRI
 nrCBV 0.80 (0.49, 1.29) .35 .59
 nrCBF 0.77 (0.46, 1.28) .31 .59
 nTMRO
2
0.72 (0.45, 1.16) .17 .58
 CET (cm3) 1.01 (0.99, 1.02) .36 .59
 NE (cm3) 1.00 (1.00, 1.01) .87 .95
Change between baseline and first follow-up MRI
 nrCBV 1.08 (0.40, 2.91) .88 .95
 nrCBF 0.87 (0.30, 2.49) .79 .95
 nTMRO
2
1.03 (0.42, 2.50) .95 .95
 CET (cm3) 0.96 (0.94, 0.98) .001 .011*
 NE (cm3) 0.99 (0.99, 1.00) .04 .18
Note.—Data in parentheses are 95% confidence intervals. CET = contrast-enhanced tumor volume, FDR = false discovery rate, NE = non-
contrast enhanced T2 fluid-attenuated inversion recovery signal abnormality, nrCBF = Gaussian-normalized relative cerebral blood volume, 
nrCBV = Gaussian-normalized relative cerebral blood volume, nTMRO
2
 = Gaussian-normalized tumor metabolic rate of oxygen.
* Quantitative interaction indicating benefit for the non-bevacizumab group (Fig E5 [online]). The given hazard ratios and P values are 
from the models’ interaction term (imaging parameter: treatment effect).
was an independent predictor of OS for the BEV group (hazard 
ratio, 2.10; 95% CI: 1.38, 3.19; P , .001), but not for the non-
BEV group (hazard ratio, 0.27; 95% CI: 0.06, 1.35; P = .11) 
(Fig 4). Despite this finding, there was no predictive association 
between nrCBV dynamics and the effect of bevacizumab treat-
ment (Table 3). Specifically, OS curves between the BEV group 
with decreasing nrCBV and the non-BEV group, regardless of 
increasing or decreasing nrCBV, were similar (Fig 5, B). Only 
patients in the BEV group with an increase in nrCBV demon-
strated a comparatively shorter OS (Fig 5, B).
Discussion
There remains an unmet clinical need for easily and ideally 
noninvasively accessible surrogate biomarkers able to delin-
eate molecular activity and predict outcome to antiangio-
genic treatment in patients with glioblastoma (10,17,21). 
We aimed to address these needs by analyzing the dynamic 
susceptibility contrast-enhanced (DSC) MRI data from the 
prospective randomized controlled multicenter phase II 
and III European Organization for Research and Treatment 
of Cancer 26101 trial. We applied a robust postprocessing 
workflow including harmonization and central processing of 
DSC MRI data with longitudinal quantification of Gaussian-
normalized relative cerebral blood volume (nrCBV, reflecting 
angiogenesis), Gaussian-normalized relative cerebral blood 
flow (nrCBF, reflecting blood flow), and tumor metabolic 
rate of oxygen (nTMRO
2
, reflecting oxygenation status). 
We found that treatment with bevacizumab significantly 
decreases contrast-enhanced and noncontrast-enhanced T2 
fluid-attenuated inversion recovery (FLAIR) signal abnor-
mality tumor volumes (by a median of 66% and 33%; P , 
.001 each) and intratumoral angiogenesis, blood flow, and 
oxygen consumption (by a median of 16%–18%; P  .001 
each). This effect was confined to patients who were admin-
istered bevacizumab (hereafter, the BEV group), whereas pa-
tients in the group who were not administered bevacizumab 
(hereafter, the non-BEV group) showed an increase in con-
trast-enhanced and noncontrast-enhanced T2 FLAIR signal 
abnormality tumor volumes but unchanged perfusion param-
eters (nrCBV, nrCBV, and nTMRO
2
) in response to treat-
ment. Although these findings reflect the effectiveness of bev-
acizumab for extending progression-free survival, we found 
no predictive association in terms of overall survival (OS) 
between the effect of bevacizumab treatment and the assessed 
imaging parameters. In accordance with the literature, we 
found that the baseline contrast-enhanced tumor volume was 
an independent prognostic significance for stratifying OS (ie, 
in both BEV and non-BEV groups [14,22,23]). Moreover, we 
found superior OS rates for patients with a greater reduction 
in contrast-enhanced tumor volume in the non-BEV group 
(compared with the BEV group), which reflects the dilemma 
of bevacizumab treatment, which frequently causes a rapid 
decline in the contrast-enhancing tumor, although this may 
partly result from normalization of abnormally permeable 
vessels and not necessarily indicate a true antitumor effect 
(24). Consequently, identifying patient subsets that may ben-
efit from bevacizumab in terms of OS remains challenging 
and the optimal setting for bevacizumab in the treatment of 
glioblastoma needs further clarification.
Noninvasive characterization of intratumoral angiogenesis 
on DSC MRI has gained substantial interest for studying the 
effects of antiangiogenic agents like bevacizumab (25). Specifi-
cally, previous uncontrolled retrospective studies demonstrated 
that angiogenesis-related parameters obtained from DSC MRI 
may correlate with treatment outcome and help identify sub-
sets in which bevacizumab is most beneficial in terms of OS 
(9,10,17,18,26,27). Specifically, lower baseline values and a 
greater reduction in angiogenesis-related parameters obtained at 
DSC MRI have been linked to a favorable OS for bevacizumab 
(9,10,17,18,26,27). Despite these intriguing findings, the utility 
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26101 trial with an adequate control arm were necessary to re-
liable differentiate a truly predictive biomarker (which allows 
identification of the likelihood of sensitivity to bevacizumab 
treatment) from a prognostic biomarker (which reflects the pa-
tients overall outcome, regardless of therapy) (20). Moreover, 
several studies indicated that bevacizumab treatment restores 
of angiogenesis-related parameters obtained from DSC MRI as 
truly predictive imaging biomarkers has, to the knowledge of the 
authors, not been fully established because previous studies were 
based on the analysis of retrospective data sets (10,17,18,26,27) 
or secondary analysis of uncontrolled phase II trials (9). Conse-
quently, our results from the secondary analysis of the EORTC 
Figure 4: Multivariable Cox proportional hazards regression model for overall survival (OS) in, A, the BEV group and, B, the non-BEV group. BEV = 
bevacizumab, CE = contrast enhanced, GCIMP = glioma-CpG island methylator phenotype, LOM = lomustine, MGMT = O6-methylguanine-DNA 
methyltransferase, NE = noncontrast enhanced, nrCBV = Gaussian-normalized relative cerebral blood volume, PD = progressive disease, WHO = 
World Health Organization.
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normalization because of bevacizumab treatment, which is hy-
pothesized to be advantageous for treatment outcome (31,32). 
Instead we saw a positive linear association between nrCBV, 
nrCBF, and nTMRO
2
, which suggested that a reduction in tu-
mor angiogenesis was also associated with a reduction in tumor 
blood flow and tumor oxygenation.
Our study had limitations. First, only a subset of 254 of 596 
patients (42.6%) met the criteria for this secondary analysis, 
with sample size determined by the availability of MRI data and 
not derived from a power calculation. Second, the high crossover 
the abnormal structure and function of the tumor vasculature 
toward a more normal state and tumor blood flow and oxygen-
ation transiently increases, thus providing an opportunity to 
improve the sensitivity toward radiation therapy and/or chemo-
therapy (28). The effect of bevacizumab on tumor oxygenation 
remains controversial, with evidence supporting either vascular 
regression, which is associated with increased intratumoral hy-
poxia (29,30), or a so-called normalization of the tumor vascu-
lature, resulting in improved tumor oxygenation and cytotoxic 
chemotherapy sensitivity (31,32). We did not observe vascular 
Figure 5: Kaplan-Meier plots for overall survival (OS) comparing outcome for the bevacizumab (BEV) versus non-BEV groups in terms of, A, 
contrast-enhanced (CE) tumor volume at baseline MRI and, B, change in Gaussian-normalized relative cerebral blood volume (nrCBV) between 
baseline and first follow-up MRI. BEV = bevacizumab, CE- = tumor volume smaller than the median contrast-enhanced tumor volume at baseline, 
CE+ = tumor volume larger than the median contrast-enhanced tumor volume at baseline, nrCBV- = decreasing nrCBV between baseline and first 
follow-up MRI, nrCBV+ = increasing nrCBV between baseline and first follow-up MRI.
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rate of 66% (61 of 93 patients) in the non-BEV group who un-
derwent bevacizumab treatment following disease progression 
may have complicated the identification of predictive imaging 
biomarkers for bevacizumab. However, multivariable Cox re-
gression modeling demonstrated that the presence of crossover 
(sequence of treatment) was not a relevant confounder. Third, 
the randomization ratio in the EORTC 26101 trial led to an 
unbalanced distribution of patients in the BEV and non-BEV 
treatment arm. This resulted in a lower number of patients in 
the non-BEV treatment arm and could have reduced statistical 
power. Fourth, the follow-up measurements in our study (6–7 
weeks after treatment initiation) may have been outside of the 
window during which vascular normalization occurs. Specifi-
cally, vascular normalization and improved tumor oxygenation is 
believed to occur from a few days until 4–5 weeks after initiation 
of bevacizumab treatment, whereas the follow-up measurement 
in our study may already fall within the phase of microvascular 
rarefaction and thus may have hampered the assessment of the 
vascular normalization theory (31).
In conclusion, secondary analysis of the European Organiza-
tion for Research and Treatment of Cancer 26101 trial demon-
strates that bevacizumab decreases tumor volumes, intratumoral 
angiogenesis, and oxygen consumption, thereby reflecting its ef-
fectiveness for extending progression-free survival. However, nei-
ther the suggested vascular normalization theory nor the value 
of assessing the extent of angiogenesis or oxygen consumption 
at dynamic susceptibility MRI as potential predictive biomark-
ers for stratifying overall survival in patients treated with bevaci-
zumab could be substantiated.
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